Research Digest High Evidence

Retatrutide TRIUMPH-4: 28.7% Weight Loss Combined with Osteoarthritis Pain Relief

Eli Lilly's triple-agonist retatrutide achieves unprecedented 28.7% weight loss while significantly reducing knee osteoarthritis pain in the TRIUMPH-4 trial, demonstrating benefits beyond metabolic effects.

PepCodex Research Team
7 min read
#retatrutide #triple-agonist #obesity #osteoarthritis

Eli Lilly has reported exceptional results from the TRIUMPH-4 trial, demonstrating that the triple-agonist peptide retatrutide achieved 28.7% weight loss while simultaneously providing clinically meaningful improvements in knee osteoarthritis pain and function. These findings position retatrutide as a potentially transformative treatment that addresses both obesity and its musculoskeletal consequences.

What We Know

The TRIUMPH-4 trial enrolled adults with obesity and moderate-to-severe knee osteoarthritis, evaluating once-weekly subcutaneous retatrutide at the highest planned commercial dose over 72 weeks [triumph-4-results]. This trial represents part of the broader TRIUMPH program examining retatrutide across diverse populations with obesity and related conditions.

Weight Loss Results

Participants receiving retatrutide achieved mean weight loss of 28.7% from baseline at 72 weeks, compared to approximately 4% with placebo [lilly-press-release]. This exceeds the weight loss observed with any previously tested pharmacological agent, approaching levels historically associated only with bariatric surgery.

The magnitude of weight loss observed with retatrutide reflects its unique triple-agonist mechanism, simultaneously activating three receptors involved in metabolic regulation:

GLP-1 receptor: Reduces appetite, enhances satiety, and improves glucose-dependent insulin secretion through mechanisms similar to semaglutide and the GLP-1 component of tirzepatide.

GIP receptor: Glucose-dependent insulinotropic polypeptide enhances the metabolic effects of GLP-1 and may independently improve fat oxidation and energy expenditure.

Glucagon receptor: Promotes hepatic fat oxidation and thermogenesis, potentially contributing additional weight loss beyond what dual agonists achieve [lancet-retatrutide].

Osteoarthritis Outcomes

Beyond weight loss, TRIUMPH-4 evaluated validated measures of knee osteoarthritis symptoms and function. Results demonstrated:

  • Significant reduction in WOMAC pain scores (Western Ontario and McMaster Universities Osteoarthritis Index), the standard measure of OA-related joint pain
  • Improved physical function as measured by WOMAC function subscales
  • Reduced stiffness in affected joints
  • Higher proportion achieving clinically meaningful improvement in pain compared to placebo

The osteoarthritis benefits appeared to correlate with weight loss magnitude, though whether the relationship is purely mechanical or involves additional mechanisms remains under investigation.

The Obesity-Osteoarthritis Connection

Knee osteoarthritis affects an estimated 250 million people globally, with obesity representing one of the strongest modifiable risk factors [oa-obesity-link]. The relationship operates through multiple mechanisms:

Mechanical loading: Excess body weight increases compressive forces on weight-bearing joints, accelerating cartilage degradation. Each pound of body weight translates to approximately three to four pounds of additional force on knee joints during walking.

Inflammatory factors: Adipose tissue produces inflammatory cytokines and adipokines that may contribute to cartilage degradation independent of mechanical effects. Obesity creates a state of chronic low-grade inflammation that affects joint tissues.

Metabolic effects: Dysregulated lipid and glucose metabolism in obesity may directly impair cartilage health through mechanisms that are increasingly understood.

Weight loss through any means typically improves OA symptoms, but the magnitude of improvement with retatrutide appears substantial, potentially reflecting the combination of dramatic weight reduction and metabolic improvements.

What We Don’t Know

Despite the impressive results, important questions remain as retatrutide progresses toward potential approval.

Structural joint outcomes: TRIUMPH-4 evaluated symptoms, not joint structure. Whether retatrutide slows cartilage loss, reduces osteophyte formation, or prevents OA progression as assessed by imaging remains unknown. Symptomatic improvement is meaningful to patients, but disease modification would represent a more profound benefit.

Durability after treatment cessation: The trial protocol maintained treatment throughout the study period. What happens to both weight and OA symptoms if treatment stops has not been characterized. Some weight regain is typical when obesity medications are discontinued, and the downstream effects on joints would be important to understand.

Long-term safety: The 72-week duration provides substantial safety data, but retatrutide has novel pharmacology as the first triple-agonist to reach this stage of development. Longer observation will be needed to fully characterize its safety profile, particularly regarding any effects of chronic glucagon receptor activation.

Comparative Questions

How retatrutide compares to tirzepatide (which activates GLP-1 and GIP but not glucagon receptors) in clinical practice remains unclear. The greater weight loss with retatrutide comes with a different side effect profile, and individual patients may respond differently to each agent. No head-to-head comparison exists.

The tolerability analysis from TRIUMPH-4 showed gastrointestinal adverse events, including nausea, vomiting, and diarrhea, consistent with other incretin-based therapies. These effects were most common during dose escalation and generally diminished over time, but rates may have been somewhat higher than observed with tirzepatide, potentially reflecting the glucagon receptor activity.

How Strong Is the Evidence?

The evidence from TRIUMPH-4 qualifies as strong for the specific outcomes measured. The trial was randomized, double-blind, and placebo-controlled, employing validated outcome measures and achieving robust statistical significance [triumph-4-results].

Strengths:

  • Large trial with adequate statistical power
  • Long duration (72 weeks) relative to most obesity trials
  • Dual assessment of weight and functional outcomes
  • Consistent with findings from other TRIUMPH program trials

Limitations:

  • Single trial for this specific population (obesity + OA)
  • Symptomatic rather than structural OA outcomes
  • Treatment period only; no post-discontinuation follow-up reported
  • The 28.7% weight loss represents mean results; individual responses vary

The findings align with mechanistic expectations and results from other retatrutide trials, strengthening overall confidence. The previous phase 2 data published in The Lancet demonstrated comparable weight loss in a general obesity population [lancet-retatrutide].

What’s Next

Several developments will shape retatrutide’s path forward.

Regulatory submissions: Eli Lilly is expected to submit retatrutide for regulatory approval based on the TRIUMPH program data. The FDA will evaluate the benefit-risk profile and determine appropriate labeling, including whether OA-related claims can be included.

Broader population data: Other TRIUMPH trials are examining retatrutide in obesity with type 2 diabetes, obesity with obstructive sleep apnea, and general obesity populations. These data will provide a comprehensive picture of the drug’s effects across different patient types.

Cardiovascular outcomes: A cardiovascular outcome trial (CVOT) is underway to determine whether retatrutide reduces major adverse cardiovascular events, which would represent an important benefit beyond weight loss. These data will likely take several years to mature.

Market positioning: Retatrutide will likely launch after tirzepatide has established market presence. How physicians and payers evaluate the incremental weight loss against potential differences in tolerability and cost will influence adoption patterns.

Manufacturing and supply: The pharmaceutical industry has faced significant challenges meeting demand for GLP-1 agonists. Eli Lilly’s manufacturing capacity and ability to ensure reliable supply will affect retatrutide’s commercial success.

OA-specific development: Whether Lilly pursues a formal OA indication, which would require additional trials with appropriate endpoints including potentially imaging or structural outcomes, remains to be seen. The TRIUMPH-4 data could support inclusion of pain improvement in labeling without a distinct OA indication.

The TRIUMPH-4 results demonstrate that next-generation obesity treatments can provide benefits extending beyond metabolic parameters to improve quality of life through reduced pain and improved physical function. For the millions living with both obesity and osteoarthritis, this combination of effects represents potentially meaningful clinical progress.

This information is provided for educational purposes only and does not constitute medical advice. Patients should discuss treatment options with qualified healthcare providers.

Sources & Citations

Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.